| Year |
Citation |
Score |
| 2021 |
Lo JA, Kawakubo M, Juneja VR, Su MY, Erlich TH, LaFleur MW, Kemeny LV, Rashid M, Malehmir M, Rabi SA, Raghavan R, Allouche J, Kasumova G, Frederick DT, Pauken KE, ... ... Mullins DW, et al. Epitope spreading toward wild-type melanocyte-lineage antigens rescues suboptimal immune checkpoint blockade responses. Science Translational Medicine. 13. PMID 33597266 DOI: 10.1126/scitranslmed.abd8636 |
0.682 |
|
| 2020 |
Kalyan S, Bazett M, Sham HP, Bosiljcic M, Luk B, Dhanji S, Costa AM, Wong SWY, Netea MG, Mullins DW, Gunn H. Distinct inactivated bacterial-based immune modulators vary in their therapeutic efficacies for treating disease based on the organ site of pathology. Scientific Reports. 10: 5901. PMID 32246043 DOI: 10.1038/S41598-020-62735-Z |
0.38 |
|
| 2019 |
Bellmann L, Cappellano G, Schachtl-Riess JF, Prokopi A, Seretis A, Ortner D, Tripp CH, Brinckerhoff CE, Mullins DW, Stoitzner P. A TLR7 agonist strengthens T and NK cell function during BRAF-targeted therapy in a preclinical melanoma model. International Journal of Cancer. PMID 31702822 DOI: 10.1002/Ijc.32777 |
0.743 |
|
| 2019 |
Sutcliffe S, Kalyan S, Pankovich J, Chen JMH, Gluck R, Thompson D, Bosiljcic M, Bazett M, Fedorak RN, Panaccione R, Axler J, Marshall JK, Mullins DW, Kabakchiev B, McGovern DPB, et al. Novel Microbial-Based Immunotherapy Approach for Crohn's Disease. Frontiers in Medicine. 6: 170. PMID 31380382 DOI: 10.3389/Fmed.2019.00170 |
0.327 |
|
| 2019 |
Ding LW, Sun QY, Edwards JJ, Fernández LT, Ran XB, Zhou SQ, Scolyer RA, Wilmott JS, Thompson JF, Doan N, Said JW, Venkatachalam N, Xiao JF, Loh XY, Pein M, ... ... Mullins DW, et al. LNK suppresses interferon signaling in melanoma. Nature Communications. 10: 2230. PMID 31110180 DOI: 10.1038/S41467-019-09711-Y |
0.389 |
|
| 2018 |
Alexander MP, Fiering SN, Ostroff GR, Cramer RA, Mullins DW. Beta-glucan-induced inflammatory monocytes mediate antitumor efficacy in the murine lung. Cancer Immunology, Immunotherapy : Cii. PMID 30167860 DOI: 10.1007/S00262-018-2234-9 |
0.444 |
|
| 2018 |
Bazett M, Costa AM, Bosiljcic M, Anderson RM, Alexander MP, Wong SWY, Dhanji S, Chen JM, Pankovich J, Lam S, Sutcliffe S, Gunn H, Kalyan S, Mullins DW. Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy. Oncoimmunology. 7: e1398875. PMID 29399400 DOI: 10.1080/2162402X.2017.1398875 |
0.483 |
|
| 2017 |
Butler KL, Clancy-Thompson E, Mullins DW. CXCR3(+) monocytes/macrophages are required for establishment of pulmonary metastases. Scientific Reports. 7: 45593. PMID 28358049 DOI: 10.1038/Srep45593 |
0.79 |
|
| 2017 |
Varn FS, Wang Y, Mullins DW, Fiering SN, Cheng C. Systematic pan-cancer analysis reveals immune cell interactions in the tumor microenvironment. Cancer Research. PMID 28126714 DOI: 10.1158/0008-5472.Can-16-2490 |
0.557 |
|
| 2016 |
Varn FS, Mullins DW, Arias-Pulido H, Fiering S, Cheng C. Adaptive immunity programs in breast cancer. Immunology. PMID 27564847 DOI: 10.1111/Imm.12664 |
0.501 |
|
| 2016 |
Mauldin IS, Wages NA, Stowman AM, Wang E, Olson WC, Deacon DH, Smith KT, Galeassi N, Teague JE, Smolkin ME, Chianese-Bullock KA, Clark RA, Petroni GR, Marincola FM, Mullins DW, et al. Topical treatment of melanoma metastases with imiquimod, plus administration of a cancer vaccine, promotes immune signatures in the metastases. Cancer Immunology, Immunotherapy : Cii. PMID 27522582 DOI: 10.1007/S00262-016-1880-Z |
0.496 |
|
| 2016 |
Mauldin IS, Wages NA, Stowman AM, Wang E, Smolkin ME, Olson WC, Deacon DH, Smith KT, Galeassi NV, Chianese-Bullock KA, Dengel LT, Marincola FM, Petroni GR, Mullins DW, Slingluff CL. Intratumoral interferon-gamma increases chemokine production but fails to increase T cell infiltration of human melanoma metastases. Cancer Immunology, Immunotherapy : Cii. PMID 27522581 DOI: 10.1007/S00262-016-1881-Y |
0.571 |
|
| 2016 |
Whipple CA, Boni A, Fisher JL, Hampton TH, Tsongalis GJ, Mellinger DL, Yan S, Tafe LJ, Brinckerhoff CE, Turk MJ, Mullins DW, Fadul CE, Ernstoff MS. The mitogen-activated protein kinase pathway plays a critical role in regulating immunological properties of BRAF mutant cutaneous melanoma cells. Melanoma Research. PMID 26974965 DOI: 10.1097/Cmr.0000000000000244 |
0.624 |
|
| 2016 |
Varn FS, Andrews EH, Mullins DW, Cheng C. Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles. Nature Communications. 7: 10248. PMID 26725977 DOI: 10.1038/Ncomms10248 |
0.389 |
|
| 2016 |
Shindiapina P, Whipple CA, Fisher JL, Hampton TH, Turk MJ, Mullins DW, Tomlinson CR, Fadul CE, Ernstoff MS. Genomic diversity in established melanoma cell lines and human melanoma tumors. Journal of Clinical Oncology. 34: e13001-e13001. DOI: 10.1200/Jco.2016.34.15_Suppl.E13001 |
0.359 |
|
| 2015 |
Bressler B, Bethel KP, Kleef R, Reynolds SL, Sutcliffe S, Mullins DW, Gunn H. Site-Specific Immunomodulator: A Novel Treatment for Crohn's Disease. Gastroenterology Research and Practice. 2015: 231243. PMID 26064087 DOI: 10.1155/2015/231243 |
0.315 |
|
| 2015 |
Clancy-Thompson E, Perekslis TJ, Croteau W, Alexander MP, Chabanet TB, Turk MJ, Huang YH, Mullins DW. Melanoma induces, and adenosine suppresses, CXCR3-cognate chemokine production and T cell infiltration of lungs bearing metastatic-like disease. Cancer Immunology Research. PMID 26048575 DOI: 10.1158/2326-6066.Cir-15-0015 |
0.818 |
|
| 2015 |
Jenkins MH, Croteau W, Mullins DW, Brinckerhoff CE. The BRAF(V600E) inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells. Matrix Biology : Journal of the International Society For Matrix Biology. 48: 66-77. PMID 25989506 DOI: 10.1016/J.Matbio.2015.05.007 |
0.626 |
|
| 2015 |
Jenkins MH, Brinckerhoff CE, Mullins DW. CXCR3 signaling in BRAFWT melanoma increases IL-8 expression and tumorigenicity. Plos One. 10: e0121140. PMID 25798946 DOI: 10.1371/Journal.Pone.0121140 |
0.639 |
|
| 2015 |
Mauldin IS, Wages NA, Stowman AM, Wang E, Smolkin ME, Olson WC, Deacon DH, Smith KT, Galeassi N, Teague JE, Clark RA, Marincola FM, Petroni GR, Mullins DW, Slingluff CL. Pilot clinical trials testing the safety and effects on the metastatic melanoma microenvironment of intratumoral interferon-gamma or imiquimod, plus a multipeptide melanoma vaccine Journal For Immunotherapy of Cancer. 3. DOI: 10.1186/2051-1426-3-S2-P139 |
0.516 |
|
| 2014 |
Steinberg SM, Zhang P, Malik BT, Boni A, Shabaneh TB, Byrne KT, Mullins DW, Brinckerhoff CE, Ernstoff MS, Bosenberg MW, Turk MJ. BRAF inhibition alleviates immune suppression in murine autochthonous melanoma. Cancer Immunology Research. 2: 1044-50. PMID 25183499 DOI: 10.1158/2326-6066.Cir-14-0074 |
0.743 |
|
| 2014 |
Jenkins MH, Steinberg SM, Alexander MP, Fisher JL, Ernstoff MS, Turk MJ, Mullins DW, Brinckerhoff CE. Multiple murine BRaf(V600E) melanoma cell lines with sensitivity to PLX4032. Pigment Cell & Melanoma Research. 27: 495-501. PMID 24460976 DOI: 10.1111/Pcmr.12220 |
0.66 |
|
| 2013 |
Clancy-Thompson E, King LK, Nunnley LD, Mullins IM, Slingluff CL, Mullins DW. Peptide vaccination in Montanide adjuvant induces and GM-CSF increases CXCR3 and cutaneous lymphocyte antigen expression by tumor antigen-specific CD8 T cells. Cancer Immunology Research. 1: 332-9. PMID 24377099 DOI: 10.1158/2326-6066.Cir-13-0084 |
0.803 |
|
| 2013 |
Oliver JL, Alexander MP, Norrod AG, Mullins IM, Mullins DW. Differential expression and tumor necrosis factor-mediated regulation of TNFRSF11b/osteoprotegerin production by human melanomas. Pigment Cell & Melanoma Research. 26: 571-9. PMID 23490134 DOI: 10.1111/Pcmr.12091 |
0.505 |
|
| 2013 |
Baird JR, Byrne KT, Lizotte PH, Toraya-Brown S, Scarlett UK, Alexander MP, Sheen MR, Fox BA, Bzik DJ, Bosenberg M, Mullins DW, Turk MJ, Fiering S. Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge. Journal of Immunology (Baltimore, Md. : 1950). 190: 469-78. PMID 23225891 DOI: 10.4049/Jimmunol.1201209 |
0.608 |
|
| 2013 |
Croteau W, Jenkins MH, Ye S, Mullins DW, Brinckerhoff CE. Differential mechanisms of tumor progression in clones from a single heterogeneous human melanoma. Journal of Cellular Physiology. 228: 773-80. PMID 23001823 DOI: 10.1002/Jcp.24225 |
0.676 |
|
| 2013 |
Slingluff CL, Petroni GR, Dengel L, Mullins DW, Grosh WW, Weiss GR, Strieter RM, Neese P, Nail C, Patterson JW, Olson WC, Chianese-Bullock KA. Evaluation of the safety and immunogenicity of intratumoral injection of interferon gamma (IFNg) during vaccination in patients with subcutaneous or cutaneous metastases of melanoma (Mel51; NCT00977145). Journal of Clinical Oncology. 31. DOI: 10.1200/Jco.2013.31.15_Suppl.Tps3118 |
0.538 |
|
| 2013 |
Fiering S, Baird JR, Byrne K, Lizotte P, Mullins D, turk MJ. Abstract A36: Treatment of established dermal murine B16F10 melanoma with an attenuatedToxoplasma gondiieliminates the treated tumor and stimulates systemic antitumor immunity. Cancer Research. 73. DOI: 10.1158/1538-7445.Tumimm2012-A36 |
0.575 |
|
| 2011 |
Tacke RS, Tosello-Trampont A, Nguyen V, Mullins DW, Hahn YS. Extracellular hepatitis C virus core protein activates STAT3 in human monocytes/macrophages/dendritic cells via an IL-6 autocrine pathway. The Journal of Biological Chemistry. 286: 10847-55. PMID 21282107 DOI: 10.1074/Jbc.M110.217653 |
0.314 |
|
| 2010 |
Iype T, Sankarshanan M, Mauldin IS, Mullins DW, Lorenz U. The protein tyrosine phosphatase SHP-1 modulates the suppressive activity of regulatory T cells. Journal of Immunology (Baltimore, Md. : 1950). 185: 6115-27. PMID 20952680 DOI: 10.4049/Jimmunol.1000622 |
0.456 |
|
| 2010 |
Dengel LT, Norrod AG, Gregory BL, Clancy-Thompson E, Burdick MD, Strieter RM, Slingluff CL, Mullins DW. Interferons induce CXCR3-cognate chemokine production by human metastatic melanoma. Journal of Immunotherapy (Hagerstown, Md. : 1997). 33: 965-74. PMID 20948440 DOI: 10.1097/Cji.0B013E3181Fb045D |
0.817 |
|
| 2010 |
Lucht AT, Clancy-Thompson E, Dengel LT, Strieter RM, Slingluff CL, Mullins DW. Abstract 3827: Interferons induce CXCR3-cognate chemokine production by melanoma Cancer Research. 70: 3827-3827. DOI: 10.1158/1538-7445.Am10-3827 |
0.821 |
|
| 2006 |
Slingluff CL, Chianese-Bullock KA, Bullock TN, Grosh WW, Mullins DW, Nichols L, Olson W, Petroni G, Smolkin M, Engelhard VH. Immunity to melanoma antigens: from self-tolerance to immunotherapy. Advances in Immunology. 90: 243-95. PMID 16730266 DOI: 10.1016/S0065-2776(06)90007-8 |
0.683 |
|
| 2006 |
Chang CC, Ogino T, Mullins DW, Oliver JL, Yamshchikov GV, Bandoh N, Slingluff CL, Ferrone S. Defective human leukocyte antigen class I-associated antigen presentation caused by a novel beta2-microglobulin loss-of-function in melanoma cells. The Journal of Biological Chemistry. 281: 18763-73. PMID 16648140 DOI: 10.1074/Jbc.M511525200 |
0.402 |
|
| 2006 |
Mullins DW, Engelhard VH. Limited infiltration of exogenous dendritic cells and naive T cells restricts immune responses in peripheral lymph nodes. Journal of Immunology (Baltimore, Md. : 1950). 176: 4535-42. PMID 16585543 DOI: 10.4049/Jimmunol.176.8.4535 |
0.676 |
|
| 2005 |
Yamshchikov GV, Mullins DW, Chang CC, Ogino T, Thompson L, Presley J, Galavotti H, Aquila W, Deacon D, Ross W, Patterson JW, Engelhard VH, Ferrone S, Slingluff CL. Sequential immune escape and shifting of T cell responses in a long-term survivor of melanoma. Journal of Immunology (Baltimore, Md. : 1950). 174: 6863-71. PMID 15905528 DOI: 10.4049/Jimmunol.174.11.6863 |
0.708 |
|
| 2004 |
Mullins IM, Slingluff CL, Lee JK, Garbee CF, Shu J, Anderson SG, Mayer ME, Knaus WA, Mullins DW. CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease. Cancer Research. 64: 7697-701. PMID 15520172 DOI: 10.1158/0008-5472.Can-04-2059 |
0.508 |
|
| 2004 |
Mullins D, Engelhard V. Immunization Maneuvers to Circumvent the Limited Capacity of Peripheral Lymph Nodes for Exogenous DC and Enhance Immunologic Control of Tumors Journal of Immunotherapy. 27: S28. DOI: 10.1097/00002371-200411000-00101 |
0.627 |
|
| 2003 |
Mullins DW, Sheasley SL, Ream RM, Bullock TN, Fu YX, Engelhard VH. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. The Journal of Experimental Medicine. 198: 1023-34. PMID 14530375 DOI: 10.1084/Jem.20021348 |
0.692 |
|
| 2003 |
Mullins DW, Martins RS, Elgert KD. Tumor-derived cytokines dysregulate macrophage interferon-gamma responsiveness and interferon regulatory factor-8 expression. Experimental Biology and Medicine (Maywood, N.J.). 228: 270-7. PMID 12626771 DOI: 10.1177/153537020322800305 |
0.769 |
|
| 2003 |
Bullock TN, Mullins DW, Engelhard VH. Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8+ T cells. Journal of Immunology (Baltimore, Md. : 1950). 170: 1822-9. PMID 12574347 DOI: 10.4049/Jimmunol.170.4.1822 |
0.61 |
|
| 2002 |
Norton EJ, Diekman AB, Westbrook VA, Mullins DW, Klotz KL, Gilmer LL, Thomas TS, Wright DC, Brisker J, Engelhard VH, Flickinger CJ, Herr JC. A male genital tract-specific carbohydrate epitope on human CD52: Implications for immunocontraception Tissue Antigens. 60: 354-364. PMID 12492811 DOI: 10.1034/J.1399-0039.2002.600502.X |
0.54 |
|
| 2002 |
Engelhard VH, Bullock TN, Colella TA, Sheasley SL, Mullins DW. Antigens derived from melanocyte differentiation proteins: self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunological Reviews. 188: 136-46. PMID 12445287 DOI: 10.1034/J.1600-065X.2002.18812.X |
0.777 |
|
| 2001 |
Bullock TN, Mullins DW, Colella TA, Engelhard VH. Manipulation of avidity to improve effectiveness of adoptively transferred CD8(+) T cells for melanoma immunotherapy in human MHC class I-transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 167: 5824-31. PMID 11698456 DOI: 10.4049/Jimmunol.167.10.5824 |
0.8 |
|
| 2001 |
Mullins DW, Bullock TN, Colella TA, Robila VV, Engelhard VH. Immune responses to the HLA-A*0201-restricted epitopes of tyrosinase and glycoprotein 100 enable control of melanoma outgrowth in HLA-A*0201-transgenic mice. Journal of Immunology (Baltimore, Md. : 1950). 167: 4853-60. PMID 11673489 DOI: 10.4049/Jimmunol.167.9.4853 |
0.794 |
|
| 2001 |
Mullins DW, Martins RS, Burger CJ, Elgert KD. Tumor cell-derived TGF-beta and IL-10 dysregulate paclitaxel-induced macrophage activation. Journal of Leukocyte Biology. 69: 129-37. PMID 11200057 |
0.728 |
|
| 2001 |
Mullins DW, Martins RS, Burger CJ, Elgert KD. Tumor cell-derived TGF-β and IL-10 dysregulate paclitaxel-induced macrophage activation Journal of Leukocyte Biology. 69: 129-137. DOI: 10.1189/Jlb.69.1.129 |
0.752 |
|
| 2000 |
Engelhard VH, Bullock TN, Colella TA, Mullins DW. Direct identification of human tumor-associated peptide antigens and a preclinical model to evaluate their use. Cancer Journal (Sudbury, Mass.). 6: S272-80. PMID 10874498 |
0.793 |
|
| 2000 |
Colella TA, Bullock TN, Russell LB, Mullins DW, Overwijk WW, Luckey CJ, Pierce RA, Restifo NP, Engelhard VH. Self-tolerance to the murine homologue of a tyrosinase-derived melanoma antigen: implications for tumor immunotherapy. The Journal of Experimental Medicine. 191: 1221-32. PMID 10748239 DOI: 10.1084/Jem.191.7.1221 |
0.783 |
|
| 1999 |
Mullins DW, Burger CJ, Elgert KD. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. Journal of Immunology (Baltimore, Md. : 1950). 162: 6811-8. PMID 10352302 |
0.697 |
|
| 1998 |
Mullins DW, Burger CJ, Elgert KD. Tumor growth modulates macrophage nitric oxide production following paclitaxel administration. International Journal of Immunopharmacology. 20: 537-51. PMID 9839658 DOI: 10.1016/S0192-0561(98)00047-2 |
0.737 |
|
| 1998 |
Mullins DW, Koci MD, Burger CJ, Elgert KD. Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation. Immunopharmacology and Immunotoxicology. 20: 473-92. PMID 9805229 DOI: 10.3109/08923979809031511 |
0.764 |
|
| 1998 |
Elgert KD, Alleva DG, Mullins DW. Tumor-induced immune dysfunction: the macrophage connection. Journal of Leukocyte Biology. 64: 275-90. PMID 9738653 DOI: 10.1002/Jlb.64.3.275 |
0.769 |
|
| 1997 |
Mullins DW, Walker TM, Burger CJ, Elgert KD. Taxol-mediated changes in fibrosarcoma-induced immune cell function: modulation of antitumor activities. Cancer Immunology, Immunotherapy : Cii. 45: 20-8. PMID 9353423 DOI: 10.1007/S002620050396 |
0.774 |
|
| 1997 |
Mullins DW, Alleva DG, Burger CJ, Elgert KD. Taxol, a microtubule-stabilizing antineoplastic agent, differentially regulates normal and tumor-bearing host macrophage nitric oxide production. Immunopharmacology. 37: 63-73. PMID 9285245 DOI: 10.1016/S0162-3109(97)00004-0 |
0.721 |
|
| Show low-probability matches. |